Akebia Therapeutics (AKBA)
(Real Time Quote from BATS)
$1.32 USD
-0.01 (-0.75%)
Updated Oct 18, 2024 01:16 PM ET
3-Hold of 5 3
C Value A Growth B Momentum A VGM
Income Statements
Fiscal Year end for Akebia Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 195 | 293 | 214 | 295 | 335 |
Cost Of Goods | 74 | 85 | 153 | 180 | 145 |
Gross Profit | 120 | 208 | 60 | 115 | 190 |
Selling & Adminstrative & Depr. & Amort Expenses | 167 | 287 | 326 | 491 | 476 |
Income After Depreciation & Amortization | -46 | -79 | -265 | -376 | -286 |
Non-Operating Income | 0 | 2 | 2 | -7 | 0 |
Interest Expense | 6 | 16 | 20 | 0 | 0 |
Pretax Income | -52 | -93 | -283 | -383 | -286 |
Income Taxes | 0 | 0 | 0 | 0 | -7 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -52 | -93 | -283 | -383 | -280 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -52 | -93 | -283 | -383 | -280 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -9 | -41 | -227 | -227 | -248 |
Depreciation & Amortization (Cash Flow) | 38 | 38 | 38 | 149 | 38 |
Income After Depreciation & Amortization | -46 | -79 | -265 | -376 | -286 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 187.47 | 182.78 | 165.95 | 138.46 | 118.40 |
Diluted EPS Before Non-Recurring Items | -0.28 | -0.43 | -1.70 | -1.93 | -1.63 |
Diluted Net EPS (GAAP) | -0.28 | -0.51 | -1.70 | -2.77 | -2.36 |
Fiscal Year end for Akebia Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | NA | 43.65 | 32.61 | 56.07 | 42.05 |
Cost Of Goods | NA | 17.05 | 11.61 | 19.37 | 18.01 |
Gross Profit | NA | 26.60 | 21.00 | 36.70 | 24.04 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 35.33 | 35.94 | 35.99 | 37.07 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -8.73 | -14.94 | 0.71 | -13.03 |
Non-Operating Income | NA | 2.29 | -0.55 | 0.66 | -0.04 |
Interest Expense | NA | 2.15 | 2.50 | 1.42 | 1.41 |
Pretax Income | NA | -8.58 | -17.99 | -0.05 | -14.49 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -8.58 | -17.99 | -0.05 | -14.49 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -8.58 | -17.99 | -0.05 | -14.49 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 209.71 | 204.96 | 190.50 | 188.31 |
Diluted EPS Before Non-Recurring Items | NA | -0.04 | -0.09 | 0.00 | -0.08 |
Diluted Net EPS (GAAP) | NA | -0.04 | -0.09 | 0.00 | -0.08 |